However, single-targeted therapeutics against PI3K/AKT pathway has demonstrated only modest clinical benefits, which may be attributed to high resistance caused by multiple concomitantly activated pathways in gliomas [17]. The gene discussed is AKT1; the disease is central nervous system cancer.